Minimal toxicity to myeloid progenitor cells of weekly 24-hr infusion of high-dose 5-fluorouracil: Direct evidence from colony forming unit-granulocyte and monocyte (CFU-GM) clonogenic assay

被引:14
作者
Yeh, KH
Yeh, SH
Chang, YS
Cheng, AL
机构
[1] Natl Taiwan Univ Hosp, Dept Internal Med, Taipei 10016, Taiwan
[2] Natl Taiwan Univ Hosp, Dept Oncol, Taipei 10016, Taiwan
[3] Natl Taiwan Univ, Coll Med, Ctr Canc Res, Taipei 10016, Taiwan
来源
PHARMACOLOGY & TOXICOLOGY | 2000年 / 86卷 / 03期
关键词
D O I
10.1034/j.1600-0773.2000.d01-22.x
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Although very high doses of 5-fluorouracil was used in the weekly 24-h infusion, high-dose 5-fluorouracil (2600 mg/m(2)/week) and leucovorin (500 mg/m(2)/week) protocol, myelosuppression was surprisingly low. The current study was conducted to investigate the possible mechanism underlying the low myelosuppression. To mimic the clinical situation, peripheral blood progenitor cells collected from 12 patients were used for colony forming unit-granulocyte and monocyte clonogenic assay; and 2 representative modes of 5-fluorouracil exposure (30 min. versus 24 hr) were examined for cytotoxic effects on human myeloid progenitor cells. Previous pharmacokinetic studies have estimated the concentrations of 5-fluorouracil in the bone marrow to be 200-400 mu M and 1-2 mu M for the 30 min. infusion (600-900 mg/m(2)) and the 24 hr-infusion (1000-2000 mg/m(2)) regimens, respectively. The results of our colony-forming unit-granulocyte and monocyte clonogenic assay showed that 24-hr exposure to 5-fluorouracil (2 mu M) and 30 min. exposure to 5-fluorouracil (100 mu M) resulted in 27.2% and 78.2% inhibition of the colony formation, respectively. Our data provided direct evidence which may explain why myelotoxicity is significantly less in weekly 24 hr infusion of fluorouracil than in the conventional bolus regimens.
引用
收藏
页码:122 / 124
页数:3
相关论文
共 14 条
[1]   A PHASE-II STUDY OF WEEKLY 24-HOUR INFUSION WITH HIGH-DOSE FLUOROURACIL WITH LEUCOVORIN IN COLORECTAL-CARCINOMA [J].
ARDALAN, B ;
CHUA, L ;
TIAN, EM ;
REDDY, R ;
SRIDHAR, K ;
BENEDETTO, P ;
RICHMAN, S ;
LEGASPI, A ;
WALDMAN, S ;
MORRELL, L ;
FEUN, L ;
SAVARAJ, N ;
LIVINGSTONE, A .
JOURNAL OF CLINICAL ONCOLOGY, 1991, 9 (04) :625-630
[2]  
Beerblock K, 1997, CANCER, V79, P1100, DOI 10.1002/(SICI)1097-0142(19970315)79:6<1100::AID-CNCR7>3.3.CO
[3]  
2-V
[4]  
Cheng AL, 1998, ANTICANCER RES, V18, P1267
[5]   A review of GERCOD trials of bimonthly leucovorin plus 5-fluorouracil 48-h continuous infusion in advanced colorectal cancer:: Evolution of a regimen [J].
de Gramont, A ;
Louvet, C ;
André, T ;
Tournigand, C ;
Krulik, M .
EUROPEAN JOURNAL OF CANCER, 1998, 34 (05) :619-626
[6]  
FRAILE RJ, 1980, CANCER RES, V40, P2223
[7]  
GREM JL, 1996, CANC CHEMOTHERAPY BI, P149
[8]  
Hsu CH, 1997, ONCOLOGY, V54, P275
[9]   WEEKLY HIGH-DOSE 5-FLUOROURACIL AND FOLINIC ACID AS SALVAGE TREATMENT IN ADVANCED GASTRIC-CANCER [J].
VANHOEFER, U ;
WILKE, H ;
WEH, HJ ;
CLEMENS, M ;
HARSTRICK, A ;
STAHL, M ;
HOSSFELD, DK ;
SEEBER, S .
ANNALS OF ONCOLOGY, 1994, 5 (09) :850-851
[10]  
Wilke H, 1996, ANN ONCOL, V7, P55